

ABBREVIATIONS

ACTase	aspartate carbamoyltransferase
ALT	alanine aminotransferase
6-AN	6-aminonicotinamide
Anth	anthracycline
APC Gene	adenomatous polyposis coli gene
ATP	adenosine triphosphate
AUC	area under the concentration time curve
GISCAD	Italian Group for the Study of Digestive Tract Cancer
MLM	bleomycin
CDDP	cisplatin
CF [*]	citrovorum factor
C.I.	continuous infusion
CNS	central nervous system
CR	complete tumor regression
CH ₂ H ₄ PteGlu	5,10-methylenetetrahydrofolate
5,10-CH ₂ THF (CH ₂ FH ₄)	5,10-methylenetetrahydrofolate
5-CH ₃ THF (5-CH ₃ FH ₄)	5-methyltetrahydrofolate
5-CHO-THF [*] (5-CHOFH)	5-formyltetrahydrofolate
DCC Gene	deleted in colorectal carcinoma gene
DHF	dihydrofolate
DHFR	dihydrofolate reductase
D.I.	dose intensity
DNA DSB	DNA double strand breaks
DOX	doxorubicin
DP	dypiridamole
DPD	dehydropyrimidine dehydrogenase
dThd-Pase	thymidine phosphorylase
dTMP	deoxythymidine monophosphate
dTTP	deoxythymidine triphosphate
dUMP	deoxyuridine monophosphate
EPI	epirubicin
FA [*]	folinic acid
F-DNA	fluorouridine incorporation into DNA
FdUDP	fluorodeoxyuridine diphosphate
FdUrd (FUdR)	5-fluoro-2'-deoxyuridine
FdUMP	FdUrd monophosphate
FdUTP	fluoroxymuridine triphosphate
FHX (Regimen)	5-fluorouracil+hydroxyurea+radiotherapy
FHX-L (Regimen)	5-fluorouracil+hydroxyurea+ radiotherapy+leucovorin
FPGS	folylpolyglutamate synthetase
F-RNA	fluorouridine incorporation into RNA
FT	ftorafur (tegafur)
FUH ₂	fluorodihydrouracil
FUra (5-FU)	5-fluorouracil
FUTP	FUra triphosphate
Fx	fractionation
HPLC	high performance liquid chromatography
HU	hydroxyurea
IC ₅₀	concentration of drug to inhibit growth by 50%
ICR	Institute of Cancer Research
IFN	interferon

IL	interleukin
IR	ionizing radiation
IV	intravenous
l-OHP	oxaliplatin
LV*	leucovorin
MCC Gene	mutated in colorectal carcinoma gene
MER	methanol extracted residue
MMC	mitomycin C
MMPR	6-methylmercaptapurine
MR	minor response
MTD	maximum tolerated dose
MTX	methotrexate
MX	mitoxantrone
N ⁵ -HCO-H ₄ PteGlu	5-formyltetrahydrofolate
NC	no change
NCAM	neural cell adhesion molecule
NCCTG	North Central Cancer Treatment Group
OTT	overall treatment time
PALA	N-(phosphonacetyl)-l-aspartate
PBM (Regimen)	cisplatin+bleomycin+methotrexate
PD	progressive disease
PFL (Regimen)	cisplatin+5-fluorouracil+leucovorin
PR	partial tumor regression
PRPP	phosphoribosyl-pyrophosphate
PS	performance status
Pts	patients
RFC	reduced-folate carrier
RT	radiotherapy
SACCCS	Surgical Adjuvant Colorectal Cancer Chemotherapy
SWOG	Southwest Oncology Group
THF (FH ₄)	tetrahydrofolate
TK	thymidine kinase
TMP	thymidylate
TS	thymidylate synthase
UFT	ftorafur/uracil (1:4)
UTP	uridine triphosphate
VDS	vindesine
WBC	white blood cell

* citrovorum factor, folinic acid, and leucovorin are all used to describe racemic (6R,S) 5-formyltetrahydrofolate (5-HCO-H₄PteGlu). LV is the preferred abbreviation for this volume.

AUTHOR INDEX

- Abad, A., 239
Adam, R., 169
Adkins, D. A., 133
Ahn, C., 187
Akman, S., 187
Allegra, C. J., 43, 55,
56, 119, 143, 186
Arbuck, S., 239
Ardalan, B., 55, 195
Barbour, K. W., 67
Bardon, M., 81
Barni, S., 233
Berger, F. G., 67
Berger, S. H., 67
Bertheault-Cvitkovic, F., 169
Bertrand, R., 23
Brienza, S., 169
Brown, M., 265
Calvert, A. H., 289
Cao, S., 1
Cascinu, S., 233
Chabner, B., 239
Chu, E., 143, 165
Clarke, S. J., 277
Codacci-Pisanelli, G., 9
Comella, G., 233
Creaven, P. J., 1, 253, 263
DeCabrio, J., 295
Depres-Brummer, P., 169
Diasio, R., 186
Diaz-Rubio, 165
Dolnick, B. J., 57, 65
Doroshov, J. H., 187, 195
Drake, J. C., 119
Erlichman, C., 77, 97
Eskandari, J., 209, 219
Fine, S., 77, 109
Foa, P., 233
Frei, E., 219
Giaccon, G., 233
Gibson, W., 265
Grem, J. L., 119
Goldschmidt, E., 81
Gorbunova, V. A., 253
Gorg, C., 77
Grison, X., 81
Guillot, T., 81
Gustavsson, B., 77
Haller, D., 51
Hamilton, S. R., 297, 303
Hamasaki, V., 187
Hannoun, L., 81
Hines, J., 240
Hoffman, W., 77
Houghton, J. A., 133, 165, 186
Houghton, P. J., 133, 290
Hrushesky, W., 186
Hughey, C. T., 67
Izrael, V., 81
Jackman, A. L., 265, 277, 289
Jolivet, J., 23
Judson, I. R., 277
Kastan, M. B., 291, 295
Kerr, I., 77
Kimbell, R., 265
Kohne-Wompner, C. H., 99
Kufe, 296, 303
Kurihara, M., 243, 263
Labianca, R., 233
Lefkopoulou, M., 51
Leong, L., 187
Levi, F., 169
Lotz, J. P., 81
Luporini, G., 233
MacDonald, J. S., 51, 55
Machover, D., 55, 81, 97
Margolin, K., 187
Martignoni, G., 233
Martin, D. S., 153, 185
Marquet, J., 81
Mauban, S., 81
Mayer, R. S., 51
McAtee, N., 119
Meropol, N., 220
Metzger, G., 81, 169
Mihich, E., 166, 185, 295
303, 305
Misset, J. L., 169
Moran, R., 65, 185, 295
Morgon, R. Jr. 187
Newman, E., 187
Noordhuis, P., 9
Palmeri, S., 240
Pancera, G., 233
Parc, R., 81
Peters, G. J., 9, 65
Petrelli, N. J., 55, 117, 253
Pinedo, H. M., 9
Preusser, P., 77
Priest, D. G., 31, 56
Raschko, J., 187
Richaud, J., 81
Rustum, Y. M., 1, 55, 165,
241, 253, 289, 295, 303
Saijo, N., 223
Salmon, R., 81

Schmitz, J. C., 31
Schmoll, H. J., 77, 99
Senn, H. J., 77
Sezeur, A., 81
Smid, K., 9
Sobrero, A., 97
Somlo, G., 187
Sorensen, J. M., 97, 289
Sparano, J. A., 125
Spaulding, M., 220
Steinberg, S., 119
Sugirnoto, Y., 223
Thomas Boyle, F., 265
van der Wilt, C. L., 9
van Laar, J. A. M., 9
Voeller, D., 43
Vokes, E. E., 197, 219, 240
Wadler, S., 125, 165
Walle, T., 31
Womack, E., 187
Wu, X., 57
Zaniboni, A., 233
Zhang, Z., 1
Zidani, R., 169
Zittoun, J., 81

SUBJECT INDEX

Since this symposium dealt with the topic of chemotherapy using the combination of 5-fluorouracil and leucovorin (called by one or another of its synonyms), the index does not include citations to every contribution under each of these headings. Citations were included only in the cases where the editor decided that they were warranted. Similarly, since leucovorin is called by many different names (5-formyltetrahydrofolate, citrovorum factor, folinic acid) each reference dose not appear under all the titles. Abbreviations used are those defined on p. 311.

- A2780 ovarian carcinoma cells, 227
 - CDDP+FUra combination 227C
 - CDDP+UFT combination, 227
- Abdominal pain, 259
- Acute lymphocytic leukemia, 27
- Adenomas, 299
- Adenomatous polyposis syndrome, 298
- Adjuvant, 51, 109
 - future directions, 114
 - levamisole, 111
- Alanine aminotransferase, 279
- Allopurinol, 201
 - FUra combination, 201
 - FUra+CDDP combination, 201
 - in treatment of head and neck cancer, 201
- 6-Aminonicotinamide, 159
 - PAPA+MMPR combination, 159
 - PALA+MMPR+FUra combination, 159
- Anabolism, 171
- Animal models, 4, 11, 159, 170
- Anorexia, 257-258, 279
- Anthracycline, 189-190
 - FUra+LV combination, 189
 - in treatment of breast cancer, 189
- Aspartate carbamoyltransferase, 119
- Biochemical modulation, 153
- Bleomycin, 202
 - CDDP+MTX combination, 202
 - FUra+CDDP+LV combination, 210
 - in treatment of head and neck cancer, 202
- Breast cancer, 44, 187, 280
 - CB 3717, 280
 - CD8F1 tumor (mouse), 159
 - doxorubicin, 189
 - ftorafur, 254
 - FUra/LV efficacy, 187
 - FUra (370mg/m²)/LV (200-500mg/m²), daily 188
 - FUra/LV/Anth efficacy, 189
 - FUra/LV/MX efficacy, 189
 - human MCF-7 cell line, 44
- Breast cancer (cont'd)
 - ICI D1694, 284
 - mitoxantrone, 189
 - UFT, 244, 256
- Cardiac toxicity, 86
- Catabolism, 171
- CB 3717, 137, 265, 277
 - antitumor activity, 281
 - action sites, 278
 - clinical phase I and II trial, 279-280
 - dose limiting toxicity, 279
 - hepatic toxicity, 283
 - in treatment of breast cancer, 280
 - in treatment of colon cancer, 280
 - in treatment of hepatoma, 280
 - in treatment of mesothelioma, 280
 - in treatment of non-small cell lung cancer, 280
 - in treatment of ovarian cancer, 280
 - kidney toxicity, 279, 283
 - malaise, 280
 - mucositis, 280
 - nephrotoxicity, 280
 - pharmacokinetics, 281
 - transaminitis, 280
- Cell culture, 68, 144
- Cell cycle, 291
- Cell-matrix interactions, 299
- Cellular heterogeneity, 153
- CH₂H₂PteGlu, 69
 - analysis, 69
- Chromosome, 298
 - short arms, 299
- Chronobiology, 169
 - FUra efficacy, 169
- Chronopharmacokinetics, 173
- Chronotherapy, 169
 - cisplatin, 169
 - doxorubicin, 169
 - theprubicin, 169

Circadian changes, 171
 FUra metabolism, 171
 Cisplatin, 190, 223
 BLM+MTX combination, 202
 chronotherapy, 169
 FUra combination, 200, 227
 FUra+allopurinol combination, 201
 FUra+IFN combination, 204
 FUra+LV combination, 190
 FUra+LV+BLM combination, 210
 FUra+CDDP+VDS combination, 210
 in treatment of
 breast cancer, 190
 in treatment of head
 and neck cancer, 200
 infusion, 169
 resistance, 228
 UFT combination, 227
 UFT+MMC combination, 250
 Clonogenic assays, 134
 Colon adenocarcinoma, 11,
 87, 99, 109
 CB 3717, 280
 colon 26 (mouse), 11, 170
 colon 38 (mouse), 11, 170
 discussion, 92
 ftorafur, 254
 ftorafur+LV combination, 260
 FUra+LV combination, 52, 234
 FUra (425mg/M²)/LV (20mg/M²)
 dx5 Q4-5 wks, 52
 FUra (500mg/M²)/LV (500mg/M²)
 Wklyx6, Q8 wks, 52
 FUra+LV+IFN combination, 234
 future studies, 235
 gene therapy, 299
 human G₃/M cell line, 134
 human H630 cell line, 144
 human HCT-8 cell line, 61
 human HCT-116 cell line, 44, 69
 p53 gene mutation, 299
 randomized phase III trial, 234
 response, 87, 100
 toxicity, 86, 101
 tumor suppressor genes, 298
 UFT, 244, 256
 UFT+LV combination, 259
 Colony formation, 299
 Complete tumor regression, 5,
 87, 202, 279
 Continuous infusion, 4,
 9-16, 112
 Cross-resistance, 266
 CT scan, 245
 Cyclophosphamide, 190
 Data analysis, 85
 Degradation, 243
 Dehydroypyrimidine-
 dehydrogenase, 171
 FUra catabolism, 171
 liver, 171
 Dermatitis, 86-88
 Diarrhea, 4, 16, 53, 78, 86, 102,
 120, 126, 170, 234, 258, 284
 Dihydrofolate reductase, 58, 278
 pharmacokinetics, 172
 inhibitor, 278
 Dipyridamole, 100
 FUra+LV combination, 100
 DNA damage, 241, 291
 DNA synthesis, 171
 Doxorubicin (adriamycin), 189
 chronotherapy, 169
 FUra+LV combination, 189
 in treatment of
 breast cancer, 189
 Embryotic stem, 295
 Endoscopy, 245
 Enzyme assay, 11
 Epirubicin, 190
 FUra+LV combination, 190
 Esophagus cancer, 254
 ftorafur, 254
 Fatigue, 126, 234, 258
 FdUrd monophosphate, 5
 analysis, 69
 pools, 69
 rapid cellular metabolism, 5
 Fever, 234, 284
 5-Fluoro-2'-deoxyuridine, 1-6, 67
 antitumor activity, 5
 colon carcinoma (rat), 5
 concluding remarks, 6
 dose limiting toxicity, 4
 growth inhibition *in vitro*, 3
 HCT-8 cell line (ileocecal
 carcinoma), 3
 LV combination, 3, 70, 226
 maximally tolerated dose, 3-4
 renal cell carcinoma, 3
 role of schedule, 1
 therapeutic efficacy, 1
 toxicity, 4, 72, 226
 Fluoropyrimidines, 233
 anabolism, 171
 catabolism, 171
 5-Fluorouracil, 9, 51, 77, 99,
 133, 223
 allopurinol combination, 201
 antitumor activity, 12, 170
 biochemical pathways, 155
 bolus injection, 9, 16
 continous infusion, 9, 16, 112
 CDDP combination, 200, 227
 CDDP+INF combination, 204
 circadian scheduling, 176
 cytotoxicity, 27, 133, 154
 discussion, 14, 92
 distribution, 171
 effect on mRNA *in vitro*, 57
 effect on mRNA *in vivo*, 60
 effect TS mRNA levels, 147
 effect TS protein, 147
 HU combination, 201
 incorporation, 59, 145
 interferons combination, 125, 143
 levamisole combination, 52, 112
 LV combination, 9, 28, 52, 77,
 81, 100, 187, 224, 234
 LV+Anth combination, 189
 LV+CDDP combination, 190, 202
 LV+CDDP+BLM, combination, 210
 LV+CDDP+VDS, 210
 LV+INF combination, 128, 133
 LV+Levamisole combination, 52
 LV+MX combination, 189
 LV+DP combination, 100
 mechanism, 154
 metabolism, 171
 MTX combination, 200
 PALA combination, 153
 PALA+thymidine combination, 306

5-Fluorouracil (cont'd)
 pharmacokinetics, 11, 172
 schedule, 51-57, 188
 toxicity, 12, 53, 89, 170
 TS synthesis, 57, 147
 Folic acid, 36
 5-Formyltetrahydrofolate, 23
 cellular interaction, 23
 natural isomer, 24, 26
 unnatural isomer, 23
 Folate polyglutamate 44
 measurement, 44
 half-life, 46
 Folates, 44, 68
 assay, 85
 pools, 44, 227
 Ftorafur, 243, 253
 clinical efficacy, 247
 degradation, 243
 in treatment of
 breast cancer, 254
 in treatment of
 colon/rectum cancer, 254
 in treatment of
 esophagus cancer, 254
 in treatment of stomach
 cancer, 254
 LV combination, 259
 metabolism, 254
 MMC combination, 246
 pharmacokinetics, 254
 phosphorylation, 243
 toxicity, 245
 thymidine phosphorylase, 243
 uracil combination, 243
 FUra triphosphate, 5
 pools, 5
 Gastric carcinoma, 225, 236
 FUra+CDDP combination, 239
 FUra+LV combination,
 phase II, 236, 239
 KATO III cell line, 225
 TMK-1 cell line, 225
 UFT+CDDP+MMC combination, 250
 Gene therapy, 298
 targets, 299
 future prospects, 300
 Gene transfer, 300
 Genetic alterations, 299, 303
 Germline mutation, 298
 Glycoprotein, 299
 Granulocytopenia, 78, 120
 Head and neck cancer, 197-204, 209
 Allopurinol, 201
 FUra, 198
 FUra+allopurinol combination, 201
 FUra+CDDP combination, 200
 FUra+CDDP+IFN combination, 204
 FUra+LV+CDDP
 combination, 202, 209
 FUra+LV+CDDP +BLM
 combination, 210
 FUra+LV+CDDP+VDS combination, 210
 FUra+MTX combination, 200
 hydroxyurea, 200
 MTX, 198
 radiotherapy, 200
 Hepatoma, 280
 CB 3717, effect, 280
 Hepatotoxicity, 283
 Heterogeneity, 300
 Hexaglutamate, 70
 HPLC, 44, 120
 ACTase activity, 121
 intracellular folates, 44
 HX62 xenograft, 282
 Hydroxyurea, 200, 209
 FUra combination, 201
 ICI 198583, 265, 277
 action site, 278
 antitumor activity, 279
 TS inhibitor, 265
 ICI D1694, 265, 277-282
 antitumor activity, 282
 action site, 278
 cellular uptake, 266
 clinical study, 283
 cross-resistance, 266
 cytotoxicity, 271-273
 effect on L5178Y lymphoma, 282
 formation, 268
 hepatotoxicity, 283
 in treatment of
 breast cancer, 284
 in treatment of nasopharyngeal
 carcinoma, 284
 in treatment of
 ovarian cancer, 284
 LV effect, 269
 LV protection, 270
 nephrotoxicity, 282
 pharmacokinetics, 283
 polyglutamation, 266
 resistant cell lines, 271
 retention, 268
 structure, 270
 toxicity, 283
 transport, 266
 TS inhibition, 270, 282
 Immunomodulation, 297
 Immunogeneity, 297
 Immunohistochemistry, 299
 Immunotherapy, 210
 In Situ TS assays, 273
 Interferon, 9, 125, 143, 209
 cytotoxicity, 145
 effect TS mRNA levels, 147
 effect TS protein, 147
 effect TS synthesis, 147
 FUra combination, 125, 143
 FUra+CDDP combination, 204
 FUra+LV combination, 125, 133
 Interleukin, 210
 Ionizing radiations, 211
 in treatment of head
 and neck cancer, 211
 K562 cell (erythroleukemia), 59
 KB1BT cell, 60
 L5178Y lymphoma, 282
 Lacrimation, 86-88
 Lethargy, 279
 Leucopenia, 53, 102, 199, 258
 Leucovorin, 31, 43, 51, 190, 202
 discussion, 37, 47, 92
 dose dependence, 34
 effect, ICI D1694, 272
 FdUrd combination, 3
 ftorafur combination, 259
 FUra combination, 9, 28, 52,
 77, 81, 100, 187, 224
 FUra+CDDP combination, 190, 202
 FUra+IFN combination, 128

Leucovorin (cont'd)
 FUra+Levamisole combination, 52
 FUra+DP combination, 100
 FUra+oxaliplatin combination, 172
 ICI D1694 protection, 272
 intracellular metabolism, 43
 pharmacokinetic, 202
 schedule, 51-57, 188-189
 select absorption, 240
 toxicity, 53, 225
 TS inhibition, 9
 UFT combination, 259
 Leukemia, 27
 acute lymphocytic leukemia, 27
 human CCRF-CEM cell, 27
 murine L1210, 176
 murine P388, 227
 Levamisole 52, 111
 FUra combination, 52, 112
 FUra+LV combination, 52
 toxicity, 53
 Li Fraumeny syndrome, 296
 Liver and biliary
 tract cancers, 236
 FUra+LV combination,
 phase II, 236
 UFT, 256
 Liver metastases, 235
 Liver microsomes, 243
 Lung cancer, 224
 CB 3717, 280
 CDDP-resistant cell line, 228
 FUra/high dose LV, phase II, 224
 non-small cell cancer, 224, 228
 UFT, 256
 Malaise, 257, 280, 284
 MCF7 cell line, 61
 MEL cell line (mouse
 erythroleukemia), 59
 Membrane transport carrier, 265
 Mesothelioma, 280
 Methotrexate, 26, 198-200, 209, 266
 carrier, 266
 CDDP+MTX combination, 202
 cytotoxicity, 27
 FUra combination, 200
 in treatment of head and
 neck cancer, 198, 209
 5,10-Methylenetetrahydrofolate, 11,
 44, 203
 measurement, 46
 polyglutamates, 45
 6-Methylmercaptopyrimidine
 riboside, 158
 PALA+6-AN combination, 159
 PALA+6-AN+FUra combination, 159
 (6R)-N⁵HCO-H₄PteGlu, 28
 effect, 28
 Mice, 11
 blood sampling, 11
 colon 26, 11, 170
 colon 38, 11, 170
 L1210 leukemia, 176
 P388 leukemia, 227
 sarcoma 180, 58,
 Mitomycin C, 113
 FT combination, 246
 UFT combination, 246
 Mitoxantrone, 189
 FUra+LV combination, 189
 Mitoxantrone (cont'd)
 in treatment of
 breast cancer, 189
 UFT+CDDP combination, 250
 Molecular biology, 297
 Molecular genetics, 297
 Mononuclear cell, 119
 mRNA, 57
 amplification, 59
 FUra effect *in vitro*, 57
 FUra effect *in vivo*, 60
 FUra incorporation, 59
 FUra target, 185
 half life, 60
 levels, 147
 Mucositis, 86, 102, 120, 191,
 280, 284
 Mouth ulceration, 4
 Myeloid toxicity, 86, 279
 Myelosuppression, 4, 120, 202, 284
 Nasopharyngeal carcinoma, 284
 ICI D1694, 284
 Nausea 53, 78, 86, 258
 Neoplasia, 297
 Nephrotoxicity, 280
 Neurologic toxicity, 86
 Neutropenia, 53, 126, 290
 Northern immunoblot analysis, 147
 N-Phosphonoacetyl-L-aspartate, 6,
 119, 153
 action mechanism, 153
 effect on ACTase, 119
 FUra combination, 153
 FUra+LV combination, 120
 FUra+MMPR+6-AN combination, 159
 FUra+thymidine combination, 306
 MMPR+6-AN combination, 159
 toxicity, 120
 Nucleic acids, 146
 IFN effect, 146
 incorporation, 146, 229
 Nucleotide pools, 146
 IFN effect, 145
 Oncogenes, 298
 Ovarian cancer, 280
 CB 3717, 280
 ICI D1694, 284
 platinum resistant tumors, 280
 Overexpression, 299
 Oxaliplatin, 169
 infusion, 169
 pharmacokinetics, 172
 p53 gene, 291, 299
 alteration, 295
 colorectal carcinoma, 299
 mutation, 299
 transfected mutant, 292
 Pancreatic carcinoma, 236
 FUra+LV combination,
 phase II, 236
 UFT, 256
 Pancytopenia, 120
 Partial tumor regression, 5,
 87, 279
 Pentaglutamate, 267
 Pharmacokinetics, 11, 85, 125,
 172, 259
 CB 3717, 281
 folates, 85
 folic acid, 36

Pharmacokinetics (cont'd)
 ftorafur, 259
 FUra, 11, 172, 259
 FUra+IFN 127
 UFT, 259
 uracil, 259
 Phenotypic variant gardner syndrome, 298
 Phosphoribosyl amidotransferase, 158
 Phosphoribosyl-pyrophosphate, 156
 Phosphorylation, 243
 Piritrexim, 204
 Polyglutamation, 46
 Polyglutamates, 265
 Proliferation, 299
 Radiosensitization, 213
 Radiotherapy, 200
 Rat, 4; 227, 281
 colon carcinoma, 4
 pharmacokinetics (CB3717), 281
 Yoshida ascites carcinoma, 227
 Recombination DNA technology, 297
 Reduced folate, 33, 265
 carrier, 265, 270
 estimation, 33
 metabolism, 265
 polyglutamates, 265
 synthetase, 265
 transport, 266
 Renal cell carcinoma, 3
 2 h inf. LV/3 h inf. FdUrd
 daily x 5 for 4 wks, 3 weekly
 i.v. FdUrd (1650 mg/m²)/2 h
 inf. LV(500 mg/m²),
 phase I, (RPCI), 3
 Resistant cell Lines, 228, 271
 Retention, 268
 Rhinitis, 86
 RNA, 5
 bolt hybridization analysis, 145
 drug incorporation, 5
 isolation, 145
 species, 59
 Schedule, 51-54, 210-211,
 214, 257
 FUra+LV combination, 51
 UFT, 257
 Selectivity, 303
 Septicemia, 102
 Short-exposure conditions, 273
 Skin rash, 120
 Stomach cancer, 244
 UFT, 244, 256
 Stomatitis, 4, 53, 78, 86, 126, 257
 Structural abnormality, 299
 p53 gene, 299
 Suppressor genes, 298
 Survival, 87, 170, 248
 Target organs, 171
 Tetraglutamate, 267
 Theprubicin, 169
 chronotherapy, 169
 Therapeutic index, 204, 293
 THoracic pain, 88
 Thrombocytopenia, 199, 258
 Thymidine, 229, 274
 FUra+PALA combination, 306
 Thymidylate synthase, 13,
 61, 70, 143
 activity, 13, 69, 274
 binding assay, 145
 biosynthesis measurement, 145
 discussion, 138, 148
 FdUMP binding, 69
 inhibitor, CB3717, 137, 280
 inhibitor, ICI 198583, 282
 inhibitor, ICI D1694, 265
 in situ assays, 273
 levels, 69
 mRNA levels, 147
 optimal inhibition, 234
 protein, 147
 Thyroid cancer, 256
 UFT, 256
 Transaminitis, 280
 Transfection, 299
 Treatment protocols, 83
 Triglutamate, 268
 Tritiated thymidine, 299
 Tumorigenicity, 299
 Tumor suppression, 299
 UFT (Tegafur/Uracil), 243
 biochemical pathways, 256
 in treatment of
 breast cancer, 256
 CDDP+MMC combination, 250
 clinical efficacy, 247, 256
 clinical experience, 243
 in treatment of
 bile duct cancer, 256
 in treatment of
 colon/rectum cancer, 256
 in treatment of gall
 bladder cancer, 256
 in treatment of head and
 neck cancer, 256
 in treatment of
 liver cancer, 256
 in treatment of lung cancer, 256
 in treatment of
 pancreas cancer, 256
 in treatment of
 stomach cancer, 256
 in treatment of
 thyroid cancer, 256
 LV combination, 259
 MMC combination, 246
 MTD, 258
 pharmacokinetics, 259
 schedule, 257
 toxicity, 245 257
 Vindesine, 210
 FUra+LV+CDDP combination 210
 in treatment of head and
 neck cancer, 210
 Vomiting, 53, 78, 86, 258
 Western immunoblot analysis, 147
 Xenograft, 227, 282